

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 1093)**

### VOLUNTARY ANNOUNCEMENT

#### ANTIBODY-DRUG CONJUGATE CPO204 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the antibody-drug conjugate CPO204 (the “**Product**”) developed by the Group has obtained approval of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) to initiate a Phase I, dose escalation and dose expansion study in the U.S. to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of the Product in patients with locally advanced or metastatic urothelial cancer.

The Product is a monoclonal antibody-drug conjugate which can bind to specific receptors on the tumor surface and achieve tumor cell killing by entering the cells through endocytosis and releasing toxins. The Product has demonstrated good anti-tumor effects on a variety of cancers in the preclinical studies, providing a promising prospect of demonstrating good efficacy in subsequent clinical trials. The Group will endeavor to push forward the clinical trials in the U.S. and strive to launch the Product as soon as possible.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 29 November 2022

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*